, Suivi des réponses aux traitements -patients ITK répondeurs. RC : Réponse Cytogénétique, vol.2

, Critères de réponse selon ELN 2013 et ESMO : 1 =réponse optimale ; 2 = en alerte ; 3 = en échec, RMM : Réponse Moléculaire Majeure

, RC : Réponse Cytogénétique (m : mineure ; P : partielle ; C : complète) ; RMM : Réponse Moléculaire Majeure. Critères de réponse selon ELN 2013 et ESMO : 1 =réponse optimale ; 2 = en alerte ; 3 = en échec, Suivi des réponses aux traitements -patients ITK non répondeurs ou intolérants 1 ère ligne de traitement, vol.3

D. A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood. 19 mai, vol.127, issue.20, pp.2391-405, 2016.

J. D. Rowley, A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining, Nature. juin, vol.243, issue.5405, pp.290-293, 1973.

E. Shtivelman, B. Lifshitz, R. P. Gale, and E. Canaani, Fused transcript of abl and bcr genes in chronic myelogenous leukaemia, Nature. juin, vol.315, issue.6020, pp.550-554, 1985.

J. De-la-fuente, A. Baruchel, A. Biondi, E. De-bont, M. Dresse et al., Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years, Br J Haematol, vol.167, issue.1, pp.33-47, 2014.

F. Millot, J. Guilhot, A. Baruchel, A. Petit, Y. Bertrand et al., Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study, vol.124, pp.2408-2418, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01064577

F. Millot, A. Baruchel, J. Guilhot, A. Petit, T. Leblanc et al., Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial, J Clin Oncol Off J Am Soc Clin Oncol. 10 juill, vol.29, issue.20, pp.2827-2859, 2011.

T. P. Hughes, A. Hochhaus, S. Branford, M. C. Müller, J. S. Kaeda et al., Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS), Blood, vol.116, pp.3758-65, 2010.

A. Hochhaus, R. A. Larson, F. Guilhot, J. P. Radich, S. Branford et al., Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia, N Engl J Med, vol.09, issue.10, pp.917-944, 2017.

R. Hehlmann, A. Hochhaus, M. Baccarani, and E. Leukemianet, Estimation nationale de l'incidence des cancers en France entre, Lancet Lond Engl. 28 juill, vol.370, issue.9584, 1980.

, / Maladies chroniques et traumatismes / Rapports et synthèses / Publications et outils / Accueil

M. Rohrbacher and J. Hasford, Epidemiology of chronic myeloid leukaemia (CML), Best Pract Res Clin Haematol. sept, vol.22, issue.3, pp.295-302, 2009.

H. Bower, M. Björkholm, P. W. Dickman, M. Höglund, P. C. Lambert et al., Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population, J Clin Oncol Off J Am Soc Clin Oncol, vol.20, issue.24, pp.2851-2858, 2016.

S. Bouyer, La leucémie myéloïde chronique de l'enfant et de l'adolescent : caractéristiques biologiques et cliniques au diagnostic, vol.07, p.3, 2017.

M. Suttorp and F. Millot, Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation, Hematol Am Soc Hematol Educ Program, vol.2010, pp.368-76, 2010.

M. W. Deininger, S. Bose, J. Gora-tybor, X. H. Yan, J. M. Goldman et al., Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation, Cancer Res. 1 févr, vol.58, issue.3, pp.421-426, 1998.

P. C. Nowell, The minute chromosome (Phl) in chronic granulocytic leukemia, Blut. avr, vol.8, pp.65-71, 1962.

J. Groffen, J. R. Stephenson, N. Heisterkamp, A. De-klein, C. R. Bartram et al., Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22, Cell. janv, vol.36, issue.1, pp.93-102, 1984.

A. Ravinet, G. Belille, M. Lemal, R. Veronese, L. Bay et al.,

, Bull Cancer (Paris). déc, vol.98, issue.12, pp.1403-1421, 2011.

L. Rejali, B. Poopak, M. Hasanzad, F. Sheikhsofla, A. S. Varnoosfaderani et al., Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance, Iran J Cancer Prev. mai, vol.8, issue.3, p.2334, 2015.

E. Masson, Leucémie myéloïde chronique

. Em-consulte,

N. Sorel, É. Cayssials, F. Brizard, and J. Chomel, Treatment and molecular monitoring update in chronic myeloid leukemia management, Ann Biol Clin, issue.2, pp.129-145

M. Deininger, J. M. Goldman, and J. V. Melo, The molecular biology of chronic myeloid leukemia, vol.96, 2000.

B. D. Lichty and S. Kamel-reid, Exon-skipping in BCR/ABL is induced by ABL exon 2, Biochem J. 15 mai, vol.348, pp.63-72, 2000.

S. Salesse, C. M. Verfaillie, and . Bcr/, ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia, Oncogene. déc, vol.21, issue.56, pp.8547-59, 2002.

M. Y. Gordon, C. R. Dowding, G. P. Riley, J. M. Goldman, and M. F. Greaves, Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia, Nature. 23 juill, vol.328, issue.6128, pp.342-346, 1987.

L. S. Steelman, S. C. Pohnert, J. G. Shelton, R. A. Franklin, F. E. Bertrand et al.,

R. /. Jak/stat and . Mek/erk, Akt and BCR-ABL in cell cycle progression and leukemogenesis, Leukemia. févr, vol.18, issue.2, pp.189-218, 2004.

R. Kuribara, H. Honda, H. Matsui, T. Shinjyo, T. Inukai et al., Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors, Mol Cell Biol. juill, vol.24, issue.14, pp.6172-83, 2004.

Z. Dai, R. C. Quackenbush, K. D. Courtney, M. Grove, D. Cortez et al.,

, Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway, Genes Dev. 15 mai, vol.12, issue.10, pp.1415-1439, 1998.

E. Deutsch, A. Dugray, A. B. Marangoni, E. Maggiorella, L. Vaganay et al.,

, BCR-ABL down-regulates the DNA repair protein DNA-PKcs, Blood. 1 avr, vol.97, issue.7, pp.2084-90, 2001.

A. Turhan, Biologie de la protéine de fusion BCR-ABL : progrès récents, Hématologie. 14 mars, vol.8, issue.1, pp.35-45, 2002.

E. Penserga and T. Skorski, Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene. 4 janv, vol.26, pp.11-20, 2007.

M. Baccarani, M. W. Deininger, G. Rosti, A. Hochhaus, S. Soverini et al.,

, European LeukemiaNet recommendations for the management of chronic myeloid leukemia, Blood. 8 août, vol.122, issue.6, pp.872-84, 2013.

N. Hijiya, K. R. Schultz, M. Metzler, F. Millot, and M. Suttorp, Pediatric chronic myeloid

J. Hasford, M. Pfirrmann, R. Hehlmann, N. C. Allan, M. Baccarani et al., A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group, J Natl Cancer Inst. 3 juin, vol.90, issue.11, pp.850-858, 1998.

F. Millot, P. Traore, J. Guilhot, B. Nelken, T. Leblanc et al., Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia, Pediatrics. juill, vol.116, issue.1, pp.140-143, 2005.

F. Millot, M. Suttorp, J. Guilhot, P. Sedlacek, E. Bont et al., The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): Objectives and Preliminary Results, Blood, vol.120, issue.21, pp.3741-3741, 2012.

W. Wang, J. E. Cortes, G. Tang, J. D. Khoury, S. Wang et al., Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy, Blood, vol.02, issue.22, pp.2742-50, 2016.

M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio et al., Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet, J Clin Oncol. 10 déc, vol.27, issue.35, pp.6041-51, 2009.

, La PCR quantitative -Principe de la PCR quantitative

I. Aurer, A. Butturini, and R. P. Gale, BCR-ABL rearrangements in children with Philadelphia chromosome-positive chronic myelogenous leukemia, Blood, vol.78, issue.9, pp.2407-2417, 1991.

S. K. Hasan, S. Sazawal, B. Kumar, R. Chaubey, P. Mishra et al., Childhood CML in India: b2a2 transcript is more common than b3a2, Cancer Genet Cytogenet. août, vol.169, issue.1, pp.76-83, 2006.

R. Adler, S. Viehmann, E. Kuhlisch, Y. Martiniak, S. Röttgers et al., Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia, Eur J Haematol. 1 févr, vol.82, issue.2, pp.112-120, 2009.

J. E. Sokal, E. B. Cox, M. Baccarani, S. Tura, G. A. Gomez et al., Prognostic discrimination in « good-risk » chronic granulocytic leukemia, Blood. avr, vol.63, issue.4, pp.789-99, 1984.

J. E. Sokal, M. Baccarani, S. Tura, M. Fiacchini, F. Cervantes et al., Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation, Blood. déc, vol.66, issue.6, pp.1352-1359, 1985.

J. Hasford, M. Pfirrmann, R. Hehlmann, N. C. Allan, M. Baccarani et al., A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group, J Natl Cancer Inst. 3 juin, vol.90, issue.11, pp.850-858, 1998.

J. Hasford, M. Baccarani, V. Hoffmann, J. Guilhot, S. Saussele et al., Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score, Blood. 21 juill, vol.118, issue.3, pp.686-92, 2011.

M. Pfirrmann, M. Baccarani, S. Saussele, J. Guilhot, F. Cervantes et al., Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia, Leukemia. janv, vol.30, issue.1, pp.48-56, 2016.

G. Salas, D. Glauche, I. Tauer, J. T. Thiede, C. Suttorp et al., Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?, Ann Hematol. août, vol.94, issue.8, pp.1363-71, 2015.

A. Tanizawa, Optimal management for pediatric chronic myeloid leukemia, Pediatr Int Off J Jpn Pediatr Soc. mars, vol.58, issue.3, pp.171-180, 2016.

F. Mahon, D. Réa, J. Guilhot, F. Guilhot, F. Huguet et al., Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial, Lancet Oncol, vol.11, issue.11, pp.1029-1064, 2010.

S. Sacchi, H. M. Kantarjian, T. L. Smith, S. O'brien, S. Pierce et al., Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia, J Clin Oncol Off J Am Soc Clin Oncol. mars, vol.16, issue.3, pp.882-891, 1998.

F. Guilhot, C. Chastang, M. Michallet, A. Guerci, J. L. Harousseau et al., Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group, N Engl J Med. 24 juill, vol.337, issue.4, pp.223-232, 1997.

F. Palandri, F. Castagnetti, I. Iacobucci, G. Martinelli, M. Amabile et al., The response to imatinib and interferon-? is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase, Haematologica. 1 août, vol.95, issue.8, pp.1415-1424, 2010.

F. E. Nicolini, G. Etienne, V. Dubruille, L. Roy, F. Huguet et al., Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study, Lancet Haematol. janv, vol.2, issue.1, pp.37-46, 2015.

F. Giona, M. L. Moleti, D. Giudice, I. Testi, A. M. Diverio et al., Long-term follow-up of Philadelphia chromosome-positive (Ph) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period, Semantic Scholar, vol.130, 2005.

M. Eapen, B. R. Logan, F. R. Appelbaum, J. H. Antin, C. Anasetti et al.,

F. Millot, H. Esperou, P. Bordigoni, J. Dalle, M. Michallet et al., Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Bone Marrow Transplant, vol.32, issue.10, pp.993-1002, 2003.

K. Cwynarski, I. Roberts, S. Iacobelli, A. Van-biezen, R. Brand et al., Stem cell transplantation for chronic myeloid leukemia in children, Blood. 15 août, vol.102, issue.4, pp.1224-1255, 2003.

B. J. Druker, F. Guilhot, S. G. O'brien, I. Gathmann, H. Kantarjian et al., Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia, N Engl J Med. 7 déc, vol.355, issue.23, pp.2408-2425, 2006.

B. J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal et al., Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat Med. mai, vol.2, issue.5, pp.561-567, 1996.

T. I. Mughal and J. M. Goldman, Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era, Front Biosci J Virtual Libr. 1 janv, vol.11, pp.209-229, 2006.

B. J. Druker, M. Talpaz, D. J. Resta, B. Peng, E. Buchdunger et al., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N Engl J Med. 5 avr, vol.344, issue.14, pp.1031-1038, 2001.

S. G. O'brien, F. Guilhot, R. A. Larson, I. Gathmann, M. Baccarani et al., Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia, N Engl J Med. 13 mars, vol.348, issue.11, pp.994-1004, 2003.

A. Hochhaus, S. G. O'brien, F. Guilhot, B. J. Druker, S. Branford et al., Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia, Leukemia. juin, vol.23, issue.6, pp.1054-61, 2009.

M. A. Champagne, C. H. Fu, M. Chang, H. Chen, R. B. Gerbing et al., Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group, Pediatr Blood Cancer. 15 juill, vol.57, issue.1, pp.56-62, 2011.

P. Debourdeau, A. Stancu, V. Debourdeau, and D. Serin, Allongement de l'intervalle QT secondaire aux inhibiteurs des tyrosines-kinases, Oncologie. 1 janv, vol.18, issue.1, pp.47-54, 2016.

S. Picard, K. Titier, E. G. Teilhet, E. Ducint, D. Bernard et al., Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standarddose imatinib in chronic myeloid leukemia, Blood. 15 avr, vol.109, issue.8, pp.3496-3505, 2007.

M. A. Champagne, R. Capdeville, M. Krailo, W. Qu, B. Peng et al., Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study, Blood, vol.104, issue.9, pp.2655-60, 2004.

F. Millot, J. Guilhot, B. Nelken, T. Leblanc, D. Bont et al., Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation, Leukemia. févr, vol.20, issue.2, pp.187-92, 2006.

F. Millot, J. Guilhot, A. Baruchel, A. Petit, T. Leblanc et al., Growth deceleration in children treated with imatinib for chronic myeloid leukaemia, Eur J Cancer Oxf Engl, vol.50, issue.18, pp.3206-3217, 1990.

H. Shima, M. Tokuyama, A. Tanizawa, C. Tono, K. Hamamoto et al.,

J. T. Tauer, L. C. Hofbauer, R. Jung, S. Gerdes, I. Glauche et al., Impact of LongTerm Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats, PLoS ONE

K. Vandyke, S. Fitter, A. L. Dewar, T. P. Hughes, and A. Zannettino, Dysregulation of bone remodeling by imatinib mesylate, Blood. 28 janv, vol.115, issue.4, pp.766-74, 2010.

B. Jaeger, J. T. Tauer, A. Ulmer, E. Kuhlisch, H. J. Roth et al., Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment, Med Sci Monit Int Med J Exp Clin Res. déc, vol.18, issue.12, pp.721-728, 2012.

K. R. Narayanan, D. Bansal, R. Walia, N. Sachdeva, A. Bhansali et al., Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis, Pediatr Blood Cancer. juill, vol.60, issue.7, pp.1148-53, 2013.

M. V. Rastogi, L. Stork, B. Druker, C. Blasdel, T. Nguyen et al., Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer, vol.59, pp.840-845, 2012.

F. J. Giles, G. Rosti, P. Beris, R. E. Clark, P. Le-coutre et al., Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study, Expert Rev Hematol. déc, vol.3, issue.6, pp.665-73, 2010.

A. Ha, A. , A. , S. Buhamad, J. H. Askar et al., Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia, Case Rep Oncol, vol.3, issue.2015

R. R. Shah, J. Morganroth, and D. R. Shah, Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval), Drug Saf. mai, vol.36, issue.5, pp.295-316, 2013.

D. Rea, A. S. Charbonnier, A. Coiteux, V. Cony-makhoul, P. Escoffre-barbe et al., Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques

L. Coutre, P. Rea, D. Abruzzese, E. Dombret, H. Trawinska et al., Severe peripheral arterial disease during nilotinib therapy, J Natl Cancer Inst. 7 sept, vol.103, issue.2, pp.1347-1355, 2011.

H. M. Kantarjian, N. P. Shah, J. E. Cortes, M. Baccarani, M. B. Agarwal et al.,

, Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION), Blood. 2 févr, vol.119, issue.5, pp.1123-1132, 2012.

M. Conchon, M. Freitas-cmb-de, R. Ma-do, C. , B. Junior et al., Dasatinib -clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia, Rev Bras Hematol E Hemoter, vol.33, issue.2, pp.131-140, 2011.

J. R. Andolina, S. M. Neudorf, and S. J. Corey, How I treat childhood CML, Blood. 23 févr, vol.119, issue.8, pp.1821-1851, 2012.

R. Aplenc, S. M. Blaney, L. C. Strauss, F. M. Balis, S. Shusterman et al., Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium, J Clin Oncol Off J Am Soc Clin Oncol. 1 mars, vol.29, issue.7, pp.839-883, 2011.

C. M. Zwaan, C. Rizzari, F. Mechinaud, D. L. Lancaster, T. Lehrnbecher et al., Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium, J Clin Oncol Off J Am Soc Clin Oncol. 1 juill, vol.31, pp.2460-2468, 2013.

T. H. Brümmendorf, J. E. Cortes, C. A. De-souza, F. Guilhot, L. Duvillié et al., Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial, Br J Haematol. janv, vol.168, issue.1, pp.69-81, 2015.

S. Bouchet, S. Poulette, and M. Molimard, Dosage plasmatique des inhibiteurs de tyrosine kinase

J. H. Vidal--ponatinib-;-lipton, C. Chuah, A. Guerci-bresler, G. Rosti, D. Simpson et al., Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, Lancet Oncol. 1 mai, vol.17, issue.5, pp.612-633, 2016.

M. C. Müller, F. Cervantes, H. Hjorth-hansen, J. Janssen, D. Milojkovic et al., Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel, Crit Rev Oncol Hematol. 1 déc, vol.120, pp.52-61, 2017.

J. Schoepfer, W. Jahnke, G. Berellini, S. Buonamici, S. Cotesta et al., Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1, J Med Chem. 27 sept, vol.61, issue.18, pp.8120-8155, 2018.

P. Rousselot, S. Prost, J. Guilhot, L. Roy, E. G. Legros et al., Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study, Cancer, vol.15, issue.10, pp.1791-1800, 2017.

O. Brück, S. Blom, O. Dufva, R. Turkki, H. Chheda et al., Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML, Leukemia. juill, vol.32, issue.7, pp.1643-56, 2018.

. Avelumab and . Pdf,

, Chronic Myeloid Leukaemia: ESMO Clinical Practice Guidelines | ESMO

J. P. Radich, How I monitor residual disease in chronic myeloid leukemia, Blood, vol.114, issue.16, pp.3376-81, 2009.

C. Preudhomme, J. Cayuela, J. Chomel, S. Corm, S. Hayette et al., Management of positive Philadelphia chromosome leukemia with ABL point mutations : recommendations from the FI-LMC group, Hématologie. 1 janv, vol.16, issue.1, pp.65-79, 2010.

M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio et al., Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet, J Clin Oncol Off J Am Soc Clin Oncol. 10 déc, vol.27, issue.35, pp.6041-51, 2009.

S. Branford, Monitoring and defining early response: Where to draw the line?, Best Pract Res Clin Haematol, vol.29, issue.3, pp.284-94, 2016.

C. Preudhomme, J. Cayuela, J. Chomel, S. Corm, S. Hayette et al.,

J. F. Apperley, Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia, Lancet Oncol, vol.8, issue.11, pp.1018-1047, 2007.

L. C. Crossman, B. J. Druker, and M. Deininger, hOCT 1 and resistance to imatinib, Blood. 1 août, vol.106, issue.3, pp.1133-1137, 2005.

S. Dulucq, S. Bouchet, B. Turcq, E. Lippert, E. G. Reiffers et al., Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood. 1 sept, vol.112, issue.5, pp.2024-2031, 2008.

B. Zu, Y. Li, X. Wang, D. He, Z. Huang et al., MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis, Pharmacogenomics. avr, vol.15, issue.5, pp.667-77, 2014.

F. Mahon, S. Hayette, V. Lagarde, F. Belloc, B. Turcq et al., Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression, Cancer Res. 1 déc, vol.68, issue.23, pp.9809-9825, 2008.

F. X. Mahon, M. W. Deininger, B. Schultheis, J. Chabrol, J. Reiffers et al., Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance, Blood. 1 août, vol.96, issue.3, pp.1070-1079, 2000.

F. Sanger, S. Nicklen, and A. R. Coulson, DNA sequencing with chain-terminating inhibitors, Proc Natl Acad Sci. 1 déc, vol.74, issue.12, 1977.

C. Hirase, Y. Maeda, S. Takai, and A. Kanamaru, Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor, Leuk Res. mars, vol.33, issue.3, pp.450-459, 2009.

C. Baer, W. Kern, S. Koch, N. Nadarajah, S. Schindela et al., Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia, Haematologica, vol.101, issue.7, pp.830-838, 2016.

C. Lacoste, A. Fabre, C. Pécheux, N. Lévy, M. Krahn et al., Le séquençage d'ADN à haut débit en pratique clinique, Arch Pédiatrie. 1 avr, vol.24, issue.4, pp.373-83, 2017.

E. R. Mardis, The impact of next-generation sequencing technology on genetics, Trends Genet TIG. mars, vol.24, issue.3, pp.133-174, 2008.

G. Matthijs, E. Souche, M. Alders, A. Corveleyn, S. Eck et al., Guidelines for diagnostic next-generation sequencing, Eur J Hum Genet. janv, vol.24, issue.1, pp.2-5, 2016.

, Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

D. M. Ross, S. Branford, J. F. Seymour, A. P. Schwarer, C. Arthur et al., Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study, Blood. 25 juill, vol.122, issue.4, pp.515-537, 2013.

S. Saussele, J. Richter, J. Guilhot, F. X. Gruber, H. Hjorth-hansen et al., Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial, Lancet Oncol. juin, vol.19, issue.6, pp.747-57, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01859932

D. Rea, F. E. Nicolini, M. Tulliez, F. Guilhot, J. Guilhot et al., Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study, Blood. 16 févr, vol.129, issue.7, pp.846-54, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02050833

F. Guilhot, L. Roy, P. Saulnier, and J. Guilhot, Interferon in chronic myeloid leukaemia: past and future, Best Pract Res Clin Haematol. 1 sept, vol.22, issue.3, pp.315-344, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00441364

A. Notz-carrere and . Leucémie-myéloide-chronique,

, BloodRef -hematology reference ? CML EUTOS score calculator

J. Gabert, E. Beillard, V. Van-der-velden, W. Bi, D. Grimwade et al., Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -A, Europe Against Cancer Program. Leukemia. déc, vol.17, issue.12, pp.2318-57, 2003.

N. Cross, H. E. White, D. Colomer, H. Ehrencrona, L. Foroni et al., Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia, Leukemia. mai, vol.29, issue.5, pp.999-1003, 2015.

S. Dulucq, G. Etienne, S. Morisset, E. Klein, C. Chollet et al., Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line, Ann Hematol. 23 févr, 2019.

S. Branford, Z. Rudzki, S. Walsh, A. Grigg, C. Arthur et al., High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance, Blood. 1 mai, vol.99, issue.9, pp.3472-3477, 2002.

F. Bonifazi, . Vivo-a-de, G. Rosti, F. Guilhot, J. Guilhot et al., Chronic myeloid leukemia and interferon-?: a study of complete cytogenetic responders, Blood, vol.15, issue.10, 2001.

Y. Belkacémi, B. Rio, and E. Touboul, Irradiation corporelle totale: techniques, dosimétrie et complications, Cancer/Radiothérapie. 1 mars, vol.3, issue.2, pp.162-71, 1999.

A. S. Wayne, C. R. Macedo, T. Szczudlo, and R. C. Woodman, Nilotinib Treatment in Pediatric Patients (pts) with Philadelphia Chromosome-Positive (Ph+) Leukemia Refractory to Prior Tyrosine Kinase Inhibitor (TKI) Therapy: Results from Nilotinib Compassionate Use Program, Blood, vol.112, issue.11, pp.4264-4264, 2008.

F. Millot, J. Guilhot, M. Suttorp, A. M. Güne?, P. Sedlacek et al., Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents, Haematologica, vol.102, issue.10, pp.1704-1712, 2017.

L. Noens, M. Lierde, . Van, R. D. Bock, G. Verhoef et al., Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study, Blood. 28 mai, vol.113, issue.22, pp.5401-5412, 2009.

D. Marin, A. Bazeos, F. Mahon, L. Eliasson, D. Milojkovic et al., Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib, J Clin Oncol. 12 avr, vol.28, issue.14, pp.2381-2389, 2010.

J. Reiffers and F. Mahon, Leucémie myéloïde chronique : étude critique des essais thérapeutiques de l'interféron-alpha recombinant et analyse des facteurs de pronostic, Hématologie. 23 juill, vol.5, issue.3, pp.225-257, 1999.

. Serment-de-galien-je-jure, en présence des maîtres de la Faculté

. D'honorer, ceux qui m'ont instruit dans les préceptes de mon art et de leur témoigner ma reconnaissance en restant fidèle à leur enseignement

, intérêt de la santé publique, ma profession avec conscience et de respecter non seulement la législation en vigueur, mais aussi les règles de l'honneur

, Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque